Therapies using cannabinoid receptor ligands will have efficiency in reducing tumor burden in malignant lymphoma

Clinical Trials, Studies and Publications:

Expression of cannabinoid receptors type 1 and type 2 in non-Hodgkin lymphoma: growth inhibition by receptor activation

Cannabinoid receptor-mediated apoptosis induced by R(+)-methanandamide and Win55,212-2 is associated with ceramide accumulation and p38 activation in mantle cell lymphoma

Cannabinoid receptor ligands mediate growth inhibition and cell death in mantle cell lymphoma

 

 

Cannabinoids encouraged cancer cell death, while decreasing growth, proliferation and metastasis of melanoma cells

Clinical Trials, Studies and Publications:

Cannabinoid receptors as novel targets for the treatment of melanoma

Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors

The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities

 

Cannabinoid compounds play a vital role in modulating the immune system and have substantial effects on natural killer cells

Clinical Trials, Studies and Publications:

Endocannabinoids in the immune system and cancer

Cannabinoids and the immune system

Several research studies show cannabis dramatically induced apoptosis (cell death) in leukemia cells

Clinical Trials, Studies and Publications:

Cannabis-induced cytotoxicity in leukemic cell lines: the role of the cannabinoid receptors and the MAPK pathway

Cannabidiol-induced apoptosis in human leukemia cells: A novel role of cannabidiol in the regulation of p22phox and Nox4 expression

p38 MAPK is involved in CB2 receptor-induced apoptosis of human leukaemia cells

Gamma-irradiation enhances apoptosis induced by cannabidiol, a non-psychotropic cannabinoid, in cultured HL-60 myeloblastic leukemia cells

Emerging evidence suggests that cannabinoids may exert beneficial effects in intestinal inflammation and cancer

Recent studies published in Pharmacology Research and the Scandinavian Journal of Gastroenterology concluded that the administration of cannabinoids “may be a promising strategy to counteract intestinal inflammation and colon cancer” and further established that colon cancer cell lines were strongly affected by cannabinoids

Clinical Trials, Studies and Publications:

Cannabinoids in intestinal inflammation and cancer

Estrogenic induction of cannabinoid CB1 receptor in human colon cancer cell lines

Cannabinoid receptor activation induces apoptosis through tumor necrosis factor alpha-mediated ceramide de novo synthesis in colon cancer cells

Researchers concluded that CBD represents the first nontoxic agent to decrease the aggressiveness of metastic breast cancer

Several studies explored the relationship between the use of cannabidiol (CBD) and the subsequent down regulation of breast cancer tumor aggressiveness. The researchers concluded that CBD represents the first nontoxic agent to decrease the aggressiveness of metastic breast cancer cells in vivo and report further evidence of how cannabinoids modulate breast cancer tumor growth and metastasis by inhibiting specific receptors.

Clinical Trials, Studies and Publications:

Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells

Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis

Crosstalk between chemokine receptor CXCR4 and cannabinoid receptor CB2 in modulating breast cancer growth and invasion

JunD is involved in the antiproliferative effect of Delta9-tetrahydrocannabinol on human breast cancer cells

Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma

Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation

The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation

THC/CBD, an endocannabinoid system modulator, has demonstrated efficacy in the treatment of Central Neuropathic Pain in patients with Multiple Sclerosis

Abstract

Central neuropathic pain (CNP), pain initiated or caused by a primary lesion or dysfunction of the central nervous system, occurs in ~28% of patients with multiple sclerosis (MS). Delta(9)-Tetrahydrocannabinol/cannabidiol (THC/CBD), an endocannabinoid system modulator, has demonstrated efficacy for up to 4 weeks in randomized controlled trials in the treatment of CNP in patients with MS.

Clinical Trials, Studies and Publications:

Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial